Crispr Therapeutics shares tumble after significant earnings miss
Jon Congleton, Chief Executive Officer of Mineralys Therapeutics , Inc. (NASDAQ:MLYS), sold 15,884 shares of common stock on July 11, 2025, for a total of $230,430. The sales were executed at a weighted-average price of $14.5071, with individual transactions occurring in a price range of $14.30 to $14.73. The transaction comes as the clinical-stage biopharmaceutical company, valued at approximately $979 million, has seen its stock surge over 52% in the past six months. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt.
Following the transaction, Congleton directly owns 846,405 shares of Mineralys Therapeutics.
The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on January 30, 2024.
In other recent news, Mineralys Therapeutics, Inc. announced positive results from its Phase 3 Launch-HTN trial of lorundrostat, a drug for treating uncontrolled or treatment-resistant hypertension. The trial, involving 1,083 participants, showed statistically significant reductions in systolic blood pressure when lorundrostat was added to existing treatments. Additionally, Mineralys reported positive topline data from its Phase 2 Explore-CKD trial, demonstrating a meaningful reduction in systolic blood pressure and urine albumin-to-creatinine ratio in chronic kidney disease patients. H.C. Wainwright reiterated a Buy rating for Mineralys, citing these results as supportive of a robust NDA submission. Meanwhile, Jefferies maintained a Hold rating, noting limited catalysts for the company in the next 12-18 months and highlighting the need for additional financing before the anticipated U.S. launch in 2027. Mineralys is also exploring potential commercial partnerships for its drug lorundrostat. The company plans to meet with the FDA in late 2025 to discuss the regulatory pathway forward. These developments reflect ongoing progress in Mineralys’s efforts to address hypertension and related conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.